Most Popular Choices
Share on Facebook 96 Printer Friendly Page More Sharing
Sci Tech    H3'ed 7/31/21

A bouquet of novel compounds: New treatment options for HIV

By       (Page 1 of 5 pages)   No comments
Follow Me on Twitter     Message Citizen News Service - CNS
Become a Fan
  (2 fans)
Shobha Shukla - CNS

We need long-acting and more effective HIV treatment options so that all people with HIV can remain healthy and live full lives, as well as we progress towards ending AIDS by 2030
We need long-acting and more effective HIV treatment options so that all people with HIV can remain healthy and live full lives, as well as we progress towards ending AIDS by 2030
(Image by CNS)
  Details   DMCA

It was 40 years ago when the first case of HIV infection was diagnosed. Since then, 77.5 million people have been infected with the virus and 34 million people have died from AIDS-related causes. While a lot has been achieved in terms of providing lifesaving antiretroviral treatment to save lives, we still lost 690,000 people living with HIV to AIDS-related illnesses in 2020. Even today more than 10 million (27%) of the 37.6 million people living with HIV are not on treatment. Moreover, "we are getting signals of HIV drug resistance, which means we need to strengthen our surveillance efforts and continue to invest in long-acting prevention and treatment tools, in the absence of an HIV vaccine, and also remember that solutions we find may not be one size that fits all", said Dr Adeeba Kamarulzaman, President of the International AIDS Society (IAS), during the closing session of the recently concluded 11th International IAS Conference on HIV Science (IAS 2021).

This article, 2nd in the series of an exclusive trilogy by CNS head and IAS HIV Science 2021 Media Fellowship Awardee Shobha Shukla, showcases some recent scientific advances made in the new drug pipeline for HIV treatment, that were discussed during IAS 2021.

Reiterating the need for developing new treatment options for people living with HIV, Professor Chloe Orkin, Clinical Professor at Queen Mary University of London said, "There are people who need new treatments- those in whom the drugs do not work anymore; or those who cannot swallow or tolerate oral medications (including children) or those who find it very challenging to adhere to daily regimens due to a variety of reasons."

Several long-acting HIV treatment modalities including injectable, oral, implant, or antibody therapy are currently under different stages of development.

Long acting cabotegravir/ rilpivirine monthly and 2-monthly injectable

This 2-drug long-acting injectable antiretroviral-based regimen for maintenance of viral load suppression consists of Rilpivirine (a non-nucleoside reverse transcriptase inhibitor) and Cabotegravir (an integrase inhibitor).

It has already been approved and licensed for use in the European Union (EU) and in USA.

Cabotegravir/ Rilpivirine intramuscular injections can be used by those people living with HIV who are on oral antiretroviral therapy. are virally suppressed for at least 3 months, and are not resistant to either of these drugs and do not have active Hepatitis B (as Cabotegravir cannot treat Hepatitis B, while a Tenofovir disoproxil fumarate (TDF) and Tenofovir Alafenamide (TAF) regimen does). Pregnant women are excluded from using this injectable, because as of now there is no clinical data for them.

Next Page  1  |  2  |  3  |  4  |  5

(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).

Rate It | View Ratings

Citizen News Service - CNS Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Citizen News Service (CNS) specializes in in-depth and rights-based, health and science journalism. For more information, please contact: www.citizen-news.org or @cns_health or www.facebook.com/cns.page
Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Management of respiratory diseases beyond drugs: Pulmonary Rehabilitation

Oxygen therapy is like a prescription drug: Use it rationally

New funding boosts research for controlling TB, malaria, dengue and leishmaniasis

Progress made but work remains on firewalling health policy from tobacco industry

Youth Changemakers at the forefront of advocating for sexual health and rights

A bouquet of novel compounds: New treatment options for HIV

To View Comments or Join the Conversation:

Tell A Friend